The study found that androgenreceptors in skin cells mainly affect the focal adhesion pathway and control the caveolin-1 gene, with implications for new treatments for related diseases.
Minoxidil may inhibit androgenreceptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.
The efficacy of degrading the androgenreceptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
The conversation discusses topical androgenreceptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.
GT20029 is a topical treatment that degrades androgenreceptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
Balding scalps have more androgenreceptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.